A pneumonia antibiotic is where it's really at, financially, for CFRX; following a wkd conference last spring, in which co's positive results treating pneumonia in vivo were presented, that Monday shares spiked from about $1 to $4 on 6mil volume PREMARKET, suggesting conference attendees - likely pros - were the buyers. Hopefully we'll see some pros start buying here. Dunno.
Fine? These crooks have twice said they'll explain bum results of phase 3 and co's murky COVID excuse for phase 3's crap results and still haven't. Whose going to invest in this POS with no product, whose IP's basically disproven till further notice. Lying F ups.
CFRX is doing just fine! :)
8 mil or so in volume, I meant.
Got it. There were just 8 million or so in block buys over several minutes, at a premium to the share price. Hedge fund trying to break shorts?
CFRX is Nasdaq not OTC.
IMHO there are better Companies trading on the OTC. That sector is dead; even if you press volume, it will only last briefly. Nobody wants OTC stocks now however the MM's will eventually start pushing them again. The question is when?
The NASDQ is being manipulated in a severe way. I have never seen this before.
I started trading in the OTC in 2009
only been trading big boards about 5yrs
but I am wondering is the spike on news chop and grind has always been like this
I feel its worse than ever, with AI algo bots reading news and filings, then spiking most news to short it back, until it finds support, then grind lower unless squeeze or news really good
has it always been like this POP&DROP or is this fairly recently new??
ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023
Hey break lower $2s resistance and off to $3 we go
Price action appeared a LITTLE more sane yesterday and today. I'm hoping shares have gradually been absorbed by real longs, from the intraday trader loons.
Looks like they do it more often than others. We'll see.
Hey! Nice to hear from you. Yea, I made the best trades pre-market. Really thought I had sold too soon as we approached $3.00 but was not meant to be. PTPI is still jiggy lol
sometimes... but I am not a big coffee drinker
my wife is
Yup another 20 cents back... definitely a rug pull
grabbed 2.39 for a trade
Historic volume. Pfizer has a stake..
As of March 24, 2023, there were 1,565,920 shares of common stock, $0.0001 par value per share, outstanding.
CFRX feels like it wants 3s
Hey bro! Do you drink Coffee? I love my early-morning Java and Expresso. :)))
nice early alert, I just got up...
daughter woke me up 4am
may just take the morning off
ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee
YONKERS, N.Y., April 26, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces the first patient has been dosed in the Phase 1b/2 of exebacase in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with chronic prosthetic joint infections (PJI) of the knee due to Staphylococcus aureus (S. aureus) or Coagulase-Negative Staphylococci (CoNS).
“We are pleased by the rapid enrollment of the first patient in our PJI study of exebacase,” said Roger J. Pomerantz, MD, President, Chief Executive Officer, and Chairman of ContraFect. “It is important to understand that surgical revision of the infected prosthesis, the current standard of care for chronic PJI, has barely improved clinical outcomes over the past several decades. We believe exebacase has the potential to replace this debilitating and expensive surgical procedure, eradicate the infection, and significantly improve quality of life for patients with chronic PJIs suffering from pain and loss of mobility.”
The Phase 1b/2 study of exebacase is a randomized, double-blind, placebo-controlled clinical study conducted in France to assess the safety, pharmacokinetics (PK), and efficacy of intra-articularly administered exebacase in patients with chronic PJI of the knee due to S. aureus or CoNS. The study will be conducted in two parts. Part I will assess efficacy at an early, six-week timepoint in addition to safety and PK. Part II will be a long-term clinical safety and efficacy follow-up for a period of up to two years. Patients entering the study will be randomized 3:1 to either exebacase or placebo, with all patients receiving study drug in the setting of a DAIR Procedure.
Data from compassionate use cases is available in the Publications & Posters and Presentations sections of the Company’s website.
I guess now we know; attendees to the pharma meeting in Europe last weekend heard the news that wasnt issued to the broader public in a PR until thursday am, such that last Monday PRE-MARKET, CFRX hit $3.50 on millions of shares.
I hope to see it trend further north here.
IMO. I own shares presently.
The ample pre-market buying yesterday was real though IMO. I'm just trying to figure out exactly what triggered it.
Because the number of flippers playing cfrx is sick. They were busy.
I sold yesterday for a small profit after getting in too high a few weeks or so ago but I bought back in today more shares.
How could CFRX trade 120 mln yesterday when only 1.6 mln OUT?
PLS Only serious answers in reply.
you mean it almost hit $3 in PM? what's the reason for the pop?
1.60 BACK TO 2.23 AFTER HITTING ALMOST $3
What CC...10,000,000 funding....
They found the bottom for now, I agree something up..
I will be too after reading some literature this afternoon. IMO